2. Chambers HF, Sande MA. Antimicrobial Agents (Continued). In Hardman JG, Limbird LE, et.al. (eds). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996, 1103-1121.

3. Brummett RE. Drug-induced ototoxicity. Drugs 1980;19:412-428.

4. Matz GJ, Lerner SA. Aminoglycoside ototoxicity. Am J Otol 1980;1:169-180.

5. Esterhal JL, Bednar J, Kimmelman CP. Gentamicin induced ototoxicity complicating treatment of chronic osteomyelitis. Clin Orthopaed Res 1986;209:186-188.

6. Matz GJ. Aminoglycoside Cochlear Ototoxicity. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 705-712.

7. Kahlmeter G, Dahlager J. Aminoglycoside toxicity and review of medical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(a):9-22.

8. Crawford J. Living without a balancing mechanism. New Engl J Med 1952;246:458.

9. Lerner SA, Schmitt BA, Seligsoh R, et.al. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986;80:98.

10. Rybak LP, Matz GJ. Auditory and vestibular effects of toxins. In Cummings CW, Frederickson JM, Harker LA, (eds). Otolaryngology--Head and Neck Surgery. St. Louis: CV Mosby, 1986, 3161.

11. Black FO, Pesznecker SC. Vestibular Ototoxicity: Clinical Considerations. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 713-734.

12. Baloh RW, Honrubia V, Yee RD, et al. Changes in the vestibulo-ocular reflex after loss of peripheral sensitivity. Ann Neurol 1984;16:222.

13. Black FO, Peterka RJ, Elardo SE. Vestibular reflex changes following aminoglycoside induced ototoxicity. Laryngoscope 1987;582.

14. Matz GJ. Clinical perspectives on ototoxic drugs. Ann Otol Rhinol Laryngol 1990;99:39.

15. Keene M, Graham JM. Clinical monitoring of the effects of gentamicin by electrocochleography. J Laryngol Otol 1984;98:11.

16. Rybak LP, Matz GJ. Ototoxicity. In Alberti PW, Ruben RJ, eds. Otologic Medicine and Surgery. New York: Churchill Livingston, 1988, 1605.

17. Physician's Desk Reference. Medical Economics Co., Montvale, NJ. 51st. ed. 1997.

18. Fowler EP. Streptomycin treatment of vertigo. Trans Am Acad Ophthalmol Otolaryngol 1948;52:239-301.

19. Hanson HV. The treatment of endolymphatic hydrops (Meniere's disease) with streptomycin. Ann Otol Rhinol Laryngol 1951;60:676-691.

20. Monsell EM, Cass SP, Rybak LP. Aminoglycoside treatment for vertigo: Development and current status. Adv Otolaryngol Head Neck Surg 1993;7.

21. Monsell EM, Cass SP, Rybak LP. Chemical labyrinthectomy. In Brackmann, ed. Otologic Surgery. Philadelphia: W.B. Saunders, 1993.

22. Hamberger CA, Hyden H, Koch H. Streptomycin bei der Menierschen Krankheit. Arch Ohren-Nasen Kehlkopth 1949;155:667-682.

23. Ruedi L. Therapeutic and toxic effects of streptomycin in otology. Laryngoscope 1951;61:613-636.

24. Schuknecht HF. Albation therapy in the management of Meniere's disease. Acta Otolaryngol 1957;132:1-42.

25. Beck C, Schmidt CL. Ten years of experience with intratympanically applied streptomycin (gentamicin) in the therapy of morbus Meniere. Arch Otolaryngol 1978;21:149-152.

26. Magnusson M, Padoan S. Delayed onset of ototoxic effects of gentamicin in treatment of Meniere's disease. Acta Otolaryngol 1991;111:671-676.

27. Nedzelski J, Schessel D, Bryce G, Pfleiderer A. Chemical labyrinthectomy: Local application ofr the treatment of unilateral Meniere's disease. Am J Otolaryngol 1992;13:18-22.

28. Van Deinse F. Medical treatment for Meniere's disease. Ned Tidschr Geneeskd 1949;31:2619-2627.

29. Hirsch BE, Kamerer DB. Intratympanic Gentamicin Therapy for Meniere's Disease. Am J Otology 1997;18:44-51.

30. Murofushi T, Halmagyi GM, Yavor RA. Intraympanic Gentamicin in Meniere's Disease: Results of Therapy. Am J Otology 1997;18:52-57.

31. Schweitzer VG. Ototoxicity of Chemotherapeutic Agents. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 759-790.

32. Hayes DM, Cvitkovic E, Golbey RB, et.al. High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-1381.

33. Aguilar-Markulis NV, Beckley S, Priore R, Mattlin C. Auditory ototoxicity effects on long-term cis-dichlorodiammine platinum II therapy in genitourinary cancer patients. J Surg Oncol 1981;16:111-123.

34. Black F, Myers E, Schramm V, et.al. Cisplatinum verstibular ototoxicity: Preliminary report. Laryngoscope 1982;92:1363-1368.

35. Schaefer SD, Wright CG, Post JD, et.al. Cisplatinum vestibular therapy toxicity. Cancer 1981;47:857-859.

36. Mahajan SL. Acute acoustic nerve palsy associated with vincristine therapy. Cancer 1981;47:2404

37. Lugassy G. Sensorineural hearing loss associated with vincristine treatment. Blut 1990;61:320-321.

38. AnonymousBoston Collaborative Drug Serveillance Program: Drug Induced deafness. JAMA 1973;224:515-516.

39. Miller RR. Deafness due to plain and ong-acting aspirin tablets. J Clin Pharmacol 1978;18:468-471.

40. Grigor RR, Spitz PW, Furst DE. Salicylate toxicity in elderly patients with rheumatoid arthritis. J Rheumatol 1987;14:60-66.

41. Insel PA. Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In Gilman AG, Goodman LS, Rall TW, et.al. (eds). Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press, 1990, 638-681.

42. McCabe PA, Dey DL. The effect of aspirin upon auditory sensitivity. Ann Otol Rhinol Laryngol 1965;74:312-325.

43. Mongan E, Kelly P, Nies K, et.al. Tinnitus as an indication of therapeutic serum salicylate levels. JAMA 1973;226:142-145.

44. Chapman P. Naproxen and sudden hearing loss. J Laryngol Otol 1982;96:163-166.

45. AnonymousAntimalarial drugs. In Miller RR, ed. CRC Handbook of Ototoxicity. Boca Raton, FL, CRC Press, 1985, 9-15.

46. Balfour AJC. The bite of Jesuits' bark. Aviation, Space, Environmental Medicine 1989;60:7:A4-5.

47. Lee CS, Heinrich J, Jung TTK. Quinine-induced ototoxicity: Alterations in cochlear blood flow. Otolaryngol Head and Neck Surg 1992;107:233

48. Mintz U, Amir J, Pinkhas J, et.al. Transient perceptive deafness due to erythromycin lactobionate. JAMA 1983;255:1122-1123.

49. Brummett RE. Ototoxic Liability of Erythromycin and Analogues. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 811-810.

50. Dabernat H, Delmas C, Seguy M, et.al. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. J Antimicrob Chemother 1991;27:19-30.

51. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91:40S-45S.

52. Geraci JR, Heilman FR, Nichols DR, et.al. Antibiotic therapy of bacterial endocarditis. VII: Vancomycin for acute micrococcal endocarditis. Staff Meet Mayo Clin 1958;172

53. Rybak LP. Ototoxicity of Loop Diuretics. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 829-844.

54. Rybak LP. Totoxicity of ethacrynic acid (a persistent clinical problem). J Laryngol Otol 1988;102:518-520.

55. Heidland H, Wigand ME. The effect of furosemide at high doses on auditory sensitivity in pateints with uremia. Klin Wochenschr 1978;87:32-36.

56. Brown CG, Ogg CS, Cameron JS, et.al. High dose furosemide in acute reversible intrinsic renal failure. Scott Med J 1974;19:35-38.

57. Rifkin SI, DeQuesada AM, Pickering MJ, et.al. Deafness associated with oral furosemide. South Med J 1978;71:86-88.

58. Meyerhoff WL, Morizono T, Wright CG, et.al. Tympanostomy tubes and otic drops. Laryngoscope 1983;93:1022

59. Lundy LB, Graham MD. Ototoxicity and ototopical medications: A survey of otolaryngologists. Presented at the Ninth Shambaugh-Shea Weekend of Otology, Chicago, Illinois, March 6-8, 1992, (Abstract).

60. Rohn GN, Meyerhoff WL, Wright CG. Ototoxicity of Topical Agents. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 747-758.

61. Brummett RE, Harris RF, Lindgren JA. Detection of ototoxicity from drugs applied topically to the middle ear space. Laryngoscope 1976;86:1177

62. Odkvist LM, Moller C, Thuomas K. Otoneurologic disturbances caused by solvent pollution. Otolaryngol Head Neck Surg 1992;106:687-692.

63. Scott PMJ, Griffiths MV. A Clinical Review of Ototoxicity. Clin Otolaryngol 1994;19:3-8.

64. Norris CH. Drugs affecting the inner ear: A review of their clinical efficacy, mechanisms of action, toxicity and place in therapy. Drugs 1988;36:754-772.

65. Aursnes J. Ototoxic effect of iodine disinfectants. Acta Oto-Larngol 1982;93:219-226.

66. Morizono T, Sikora M. The ototoxicity of topically applied providone-iodine solutions. Arch Otolaryngol 1982;108:210-213.

67. Aursnes J. Vestibular damage from chlorhexidine in guinea pigs. Acta Oto-Laryngol 1981;92:89-100.

68. Igarashi Y, Suzuki U. Cochlear ototoxicity of chlorhexidine gluconate in cats. Arch of Oto-Rhino-Laryngol 1985;242:167-176.

69. Schacht J. Biochemical Basis of Aminoglycoside Ototoxicity. In Rybak LP, ed. Ototoxicity. The Otolaryngologic Clinics of North America. Philadelphia: W.B. Saunders, 1993, 845-856.

70. Takada A, Schacht J. Calcium antagonism and reversibility of gentamicin-induced loss of cochlear microphonics in the guinea pig. Hear Res 1982;8:179b-186.

71. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat: Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986;77:1492-1500.

72. Peterka RJ, Black FO, Schoenhoff MB. Age-related changes in human vestibulo-ocular and optokinetic reflexes: Pseudorandom rotation tests. J Vest Res 1990;1:61